Estimated prevalence of ulcerative colitis and Crohn’s disease in Japan in 2014: an analysis of a nationwide survey-Reference-Cited by-同舟云学术

Estimated prevalence of ulcerative colitis and Crohn’s disease in Japan in 2014: an analysis of a nationwide survey

Published:2019-07-15 Issue:12 Volume:54 Page:1070-1077
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Murakami Yoshitaka,Nishiwaki Yuji,Oba Mari S.,Asakura Keiko,Ohfuji Satoko,Fukushima Wakaba,Suzuki Yasuo,Nakamura Yosikazu

Funder

Ministry of Health, Labour and Welfare

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00535-019-01603-8.pdf

Reference22 articles.

1. Ng SC. Epidemiology of inflammatory bowel disease: focus on Asia. Best Pract Res Clin Gastroenterol. 2014;28:363–72.

2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–544.

3. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390:2769–78.

4. Ministry of Health, Labour and Welfare. Annual Health, Labour and Welfare Report 2017. https://www.mhlw.go.jp/english/wp/wp-hw11/dl/02e.pdf . Accessed 9 Nov 2018.

5. Japan Intractable Disease Information Center. Ulcerative colitis. https://www.nanbyou.or.jp/entry/62 . Accessed 9 Nov 2018 (in Japanese).

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Patients with Ulcerative Colitis: A Real-World Retrospective Study;Biomedicines;2024-09-02

2. The Diagnostic Utility of Biochemical Markers and Intestinal Ultrasound Compared with Endoscopy in Patients with Crohn’s Disease and Ulcerative Colitis: A Systemic Review and Meta-Analysis;Journal of Clinical Medicine;2024-05-21

3. Remission Factors for Ustekinumab Treatment of Ulcerative Colitis: A Multicenter Retrospective Study of Real-World Data in Japan;Biomedicines;2024-05-17

4. Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies;Intestinal Research;2024-04-30

5. Trends in the prevalence and incidence of Crohn’s disease in Japan and the United States;International Journal of Colorectal Disease;2024-04-27